Johnson & Johnson posted a strong second quarter, with med-tech divisions notably outperforming expectations. The company recorded a 6.9% increase in overall sales, led by a 22.3% surge in cardiology device revenue. Despite significant patent expirations impacting blockbuster drug Stelara, J&J's innovative medicines division achieved nearly 5% growth. Executives highlighted promising oncology and immunology drug launches, supporting their ambition to become the leading oncology company by 2030. J&J’s med-tech strength underscores the sector’s critical role amid evolving pharmaceutical landscapes.